CERS News and Press, Cerus Corporation From 09/26/22

Workshop and Abstracts Highlight the Favorable Impacts Associated with the INTERCEPT Blood System for Platelets and the INTERCEPT Blood System for Cryoprecipitation in Clinical Settings Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry ...

U.S. stock markets have been exceedingly volatile in 2022. This turbulent environment hasn't kept some of the world's best investors on the sidelines, however. The billionaire brothers Julian and Felix Baker -- co-owners of the biotechnology focused hedge fund Baker Bros. Advisors -- ar...

Spread of monkeypox infections serves as another real-world example of the ongoing risk of emerging pathogens and the potential role for pathogen reduction technology, like the INTERCEPT Blood System, in securing the blood supply Cerus Corporation (Nasdaq: CERS) acknowledges...

Image source: The Motley Fool. Cerus (NASDAQ: CERS) Q2 2022 Earnings Call Aug 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Cerus (CERS) Q2 2022 Earnings Call Transcript

Cerus Corporation (CERS) Q2 2022 Earnings Conference Call August 4, 2022 4:30 P.M. ET Company Participants Matt Notarianni - Senior Director-Investor Relations Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevi...

Cerus press release ( NASDAQ: CERS ): Q2 GAAP EPS of -$0.05 beats by $0.02 . Revenue of $47.63M (+26.1% Y/Y) beats by $4.87M . Non-GAAP Adjusted EBITDA for the second quarter of 2022 was negative $2.4 million, compared to negative $8.2 million during the prior ...

Second Quarter 2022 is Highest Product Revenue in Company History Total Revenue of $47.6 Million Grew 26% YoY in the Second Quarter Product Revenue of $41.0 Million Grew 30% YoY in the Second Quarter Reiterating Full-Year 2022 Product Revenue Guidance Range of ...

Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2022 financial results will be released on Thursday, August 4, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management ...

ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...

Cerus Corp. presents us with softening fundamentals that look unattractive against the current macro backdrop. Investors are rewarding bottom line fundamentals in FY22 as they step up in quality, hence, CERS misses the bill on this front. Balancing the risk/reward calculus are its...